Nivolumab ( a programmed death @ -LSB- PD-@ -RSB- checkpoint inhibitor ) and ipilimumab ( a cytotoxic T-lymphocyte-associated antigen @ -LSB- CTLA-@ -RSB- checkpoint inhibitor ) have been shown to have complementary activity in metastatic melanoma .